



261 Mountain View Dr  
 Colchester, VT 05446  
 License #: TLAB0030  
 802-767-7256  
 info@onwardanalytics.biz

# Certificate of Analysis

**Client Name:** Vermont Kind  
**License Number:** SCLT0186

**Sample ID:** VT9171  
**Sample Name:** Froze Petalz x ECSD Virgin Extract  
**Sample Lot:** MANU0027-C0058  
**Sample Matrix:** Solvent Extraction Concentrates  
**Date Received:** 4/12/2024  
**Date Reported:** 4/19/2024  
**Date Tested:** 4/16/2024



## Total Terpenes (%) : 5.7241

Dominant Terpenes (%)	
beta-caryophyllene	1.7606
Myrcene	1.4704
Limonene	0.6084
alpha-Humulene	0.5602
alpha-Pinene	0.3494

## Terpenes

Standard terpene analysis utilizing Gas Chromatography – Mass Spectrometry (GC-MS; SOP-069-OA) | Test ID: #27217

Analyte	Result (%)	Result (mg/g)	LOD (mg/g)	LOQ (mg/g)
3-Carene	ND	ND	0.000002	0.002
alpha-Bisabolol	0.2163	2.163	0.000003	0.002
alpha-Humulene	0.5602	5.602	0.000002	0.002
alpha-Pinene	0.3494	3.494	0.000001	0.002
alpha-Terpinene	< LOQ	< LOQ	0.000001	0.002
alpha-Terpinolene	0.0432	0.432	0.000004	0.002
beta-caryophyllene	1.7606	17.606	0.000004	0.002
beta-Pinene	0.1712	1.712	0.000002	0.002
Camphene	0.0424	0.424	0.000001	0.002
Caryophyllene Oxide	0.0956	0.956	0.000011	0.002
Eucalyptol	ND	ND	0.000002	0.002
gamma-Terpinene	ND	ND	0.000002	0.002
Geraniol	ND	ND	0.000008	0.002
Guaiol	ND	ND	0.000007	0.002
Isopulegol	ND	ND	0.000005	0.002
Isopropyl Toluene	ND	ND	0.000003	0.002
Limonene	0.6084	6.084	0.000002	0.002
Linalool	0.2122	2.122	0.000003	0.002
Nerolidol	0.0758	0.758	0.000007	0.002
Myrcene	1.4704	14.704	0.000003	0.002
Ocimene	0.1184	1.184	0.000002	0.002
<b>Total Terpenes</b>	<b>5.7241</b>	<b>57.241</b>		

Callie Chapman  
 Lab Director  
 4/19/2024

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; and (e) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.

